AngioDynamics Q1 sales rally 6.9% to $80.9 million

• AngioDynamics (NASDAQ:ANGO) reported fiscal Q1 2027 net sales of $80.9 million, up 6.9% year over year.
• Med Tech sales increased 13.2% to $39.9 million, while GAAP net loss narrowed to $7.1 million from $10.9 million.
• Adjusted EBITDA more than doubled to $5 million, supported by higher-margin Med Tech sales and improved pricing.

AngioDynamics (NASDAQ:ANGO) reported fiscal first-quarter 2027 net sales of $80.9 million, up 6.9% from the prior-year period.

Med Tech revenue rose 13.2% to $39.9 million, with Auryon sales up 14.7% to $18.9 million and NanoKnife sales increasing 29.0% to $8.3 million.

Mechanical Thrombectomy revenue increased 6.7% to $12.0 million, as AlphaVac sales grew 37.4% while AngioVac sales declined 5.9% year over year.

Gross margin expanded 410 basis points to 59.4%, helped by pricing, a richer Med Tech mix and tariff refunds, while underlying gross margin excluding refunds was 57.8%.

The company said second-half fiscal 2027 gross margin is expected to be lower than first-half levels.

GAAP net loss narrowed to $7.1 million, or $0.17 per share, from $10.9 million, or $0.26 per share, while adjusted net loss improved to $1.8 million from $4.2 million.

Adjusted EBITDA increased to $5 million from $2.2 million, while AngioDynamics ended the quarter with $34 million in cash and no debt.